

Review of: "Personalized (tailored) treatment with antiresorptive drugs (bisphosphonates, denosumab) in patients with bone metastases from solid tumors – A “Pico” document by Rete Oncologica Piemonte-Valle D’Aosta Bone Metastatic Disease Study Group"

Pietro Ruggieri¹

¹ University of Padua

Potential competing interests: No potential competing interests to declare.

The current paper tries to give guidelines for the use of antiresorptive drugs (bisphosphonates and denosumab) in patients with bone metastases from solid tumors.

The Authors analyzed the duration of treatment, costs, side effects.

The analysis is very well performed, and the indication clear and well defined.

Even if these are the recommendations of this Study Group I think these could be good guidelines for many Centers.

For these reasons I suggest accepting the paper for publication.